1 week Ago By ABMN Staff
Arrowstreet Capital Limited Partnership acquired a new stake in shares of Insulet Co. ( NASDAQ:PODD – Free Report ) during the fourth quarter, Holdings Channel reports. The fund acquired 37,624 shares of the medical instruments supplier’s stock, valued at approximately $9,822,000.
Other hedge funds also recently added to or reduced their stakes in the company. SBI Securities Co. Ltd.
bought a new position in shares of Insulet during the fourth quarter worth about $36,000. SRS Capital Advisors Inc. raised its stake in Insulet by 43.
1% during the fourth quarter. SRS Capital Advisors Inc. now owns 186 shares of the medical instruments supplier’s stock valued at $49,000 after buying an additional 56 shares in the last quarter.
TD Private Client Wealth LLC lifted its holdings in Insulet by 32.6% during the 3rd quarter. TD Private Client Wealth LLC now owns 228 shares of the medical instruments supplier’s stock worth $53,000 after buying an additional 56 shares during the last quarter.
Friedenthal Financial acquired a new position in shares of Insulet in the 4th quarter worth approximately $57,000. Finally, Assetmark Inc. increased its holdings in shares of Insulet by 1,447.
1% in the 4th quarter. Assetmark Inc. now owns 263 shares of the medical instruments supplier’s stock valued at $69,000 after acquiring an additional 246 shares during the last quarter.
Insiders Place Their Bets In related news, EVP Eric Benjamin sold 12,394 shares of the business’s stock in a transaction that occurred on Tuesday, January 21st. The shares were sold at an average price of $280.00, for a total value of $3,470,320.
00. Following the sale, the executive vice president now directly owns 11,383 shares in the company, valued at $3,187,240. The trade was a 52.
13 % decrease in their position. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available through this link . Also, Director Wayne A.
I. Frederick sold 1,825 shares of the firm’s stock in a transaction that occurred on Tuesday, March 25th. The stock was sold at an average price of $275.
00, for a total transaction of $501,875.00. Following the sale, the director now owns 3,231 shares of the company’s stock, valued at $888,525.
The trade was a 36.10 % decrease in their ownership of the stock. The disclosure for this sale can be found here .
0.47% of the stock is currently owned by insiders. Wall Street Analysts Forecast Growth Get Our Latest Report on PODD Insulet Trading Down 4.
5 % NASDAQ:PODD opened at $245.26 on Monday. The stock has a market cap of $17.
22 billion, a price-to-earnings ratio of 42.36, a PEG ratio of 3.62 and a beta of 1.
30. The business has a fifty day moving average of $269.86 and a 200-day moving average of $259.
86. Insulet Co. has a 1 year low of $160.
19 and a 1 year high of $289.46. The company has a debt-to-equity ratio of 1.
21, a quick ratio of 2.80 and a current ratio of 3.68.
Insulet ( NASDAQ:PODD – Get Free Report ) last released its quarterly earnings results on Thursday, February 20th. The medical instruments supplier reported $1.15 EPS for the quarter, topping analysts’ consensus estimates of $1.
00 by $0.15. The company had revenue of $597.
50 million for the quarter, compared to the consensus estimate of $582.02 million. Insulet had a net margin of 20.
19% and a return on equity of 24.46%. Equities analysts predict that Insulet Co.
will post 3.92 earnings per share for the current year. Insulet Profile ( Free Report ) Insulet Corporation develops, manufactures, and sells insulin delivery systems for people with insulin-dependent diabetes.
The company's Omnipod platform includes the Omnipod 5 Automated Insulin Delivery System (Omnipod 5) which includes a proprietary AID algorithm embedded in the Pod that integrates with a third-party continuous glucose monitor to obtain glucose values through wireless bluetooth communication; Omnipod DASH that features a bluetooth enabled Pod that is controlled by a smartphone-like Personal Diabetes Manager with a color touch screen user interface; and Omnipod GO, a standalone, wearable, insulin delivery system that provides a fixed rate of continuous rapid-acting insulin for 72 hours. Further Reading Want to see what other hedge funds are holding PODD? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Insulet Co.
( NASDAQ:PODD – Free Report ). Receive News & Ratings for Insulet Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Insulet and related companies with MarketBeat.com's FREE daily email newsletter .
.
